BACKGROUNDTriple-unfavorable breast most cancers (TNBC) is highly aggressive with an elevated metastatic incidence as compared to other breast cancer subtypes. Having said that, mainly because of the absence of clinically reputable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. As